Intellipharmaceutics International Inc. (IPCIF)
USD 0.15
(N/A%)
USD 0.15
(N/A%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 2.91 Million USD | 0.0% |
| 2022 | 2.91 Million USD | -30.12% |
| 2021 | 4.17 Million USD | -31.36% |
| 2020 | 6.07 Million USD | -59.23% |
| 2019 | 14.91 Million USD | 14.14% |
| 2018 | 13.06 Million USD | 232.36% |
| 2017 | 3.93 Million USD | -0.72% |
| 2016 | 3.95 Million USD | -7.53% |
| 2015 | 4.28 Million USD | 30.96% |
| 2014 | 3.26 Million USD | -20.72% |
| 2013 | 4.12 Million USD | 30.82% |
| 2012 | 3.15 Million USD | 7.17% |
| 2011 | 2.94 Million USD | 0.0% |
| 2009 | 13.6 Million USD | -48.55% |
| 2008 | 26.43 Million USD | -44.6% |
| 2007 | 47.72 Million USD | -40.67% |
| 2006 | 80.44 Million USD | 25.79% |
| 2005 | 63.95 Million USD | 150.85% |
| 2004 | 25.49 Million USD | 94.77% |
| 2003 | 13.08 Million USD | 25.12% |
| 2002 | 10.46 Million USD | 38.56% |
| 2001 | 7.55 Million USD | 34.75% |
| 2000 | 5.6 Million USD | 14.54% |
| 1999 | 4.89 Million USD | -10.75% |
| 1998 | 5.48 Million USD | 57.15% |
| 1997 | 3.48 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 627.74 Thousand USD | 28.3% |
| 2024 Q3 | 982.37 Thousand USD | 92.04% |
| 2024 Q2 | 511.55 Thousand USD | -18.51% |
| 2023 FY | 2.91 Million USD | 0.0% |
| 2023 Q3 | 385.25 Thousand USD | -69.22% |
| 2023 Q4 | 489.26 Thousand USD | 27.0% |
| 2023 Q1 | 856.32 Thousand USD | -38.72% |
| 2023 Q2 | 1.25 Million USD | 46.19% |
| 2022 FY | 2.91 Million USD | -30.12% |
| 2022 Q1 | 784.91 Thousand USD | -55.45% |
| 2022 Q2 | 1 Million USD | 27.44% |
| 2022 Q3 | 1.08 Million USD | 8.35% |
| 2022 Q4 | 1.39 Million USD | 28.94% |
| 2021 Q2 | 1.28 Million USD | -18.29% |
| 2021 Q4 | 1.76 Million USD | 20.82% |
| 2021 Q1 | 1.57 Million USD | 4.26% |
| 2021 FY | 4.17 Million USD | -31.36% |
| 2021 Q3 | 1.45 Million USD | 13.39% |
| 2020 Q2 | 3.25 Million USD | -5.97% |
| 2020 Q3 | 3.05 Million USD | -6.37% |
| 2020 Q4 | 1.5 Million USD | -50.51% |
| 2020 FY | 6.07 Million USD | -59.23% |
| 2020 Q1 | 3.46 Million USD | -11.15% |
| 2019 FY | 14.91 Million USD | 14.14% |
| 2019 Q4 | 3.89 Million USD | -8.72% |
| 2019 Q1 | 3.42 Million USD | 5.11% |
| 2019 Q3 | 4.27 Million USD | 28.79% |
| 2019 Q2 | 3.31 Million USD | -3.18% |
| 2018 FY | 13.06 Million USD | 232.36% |
| 2018 Q1 | 1.05 Million USD | 127.88% |
| 2018 Q3 | 3.18 Million USD | -10.15% |
| 2018 Q2 | 3.54 Million USD | 236.25% |
| 2018 Q4 | 3.25 Million USD | 2.43% |
| 2017 Q1 | 2.66 Million USD | 181.53% |
| 2017 Q2 | 2.46 Million USD | -7.49% |
| 2017 Q3 | 2.58 Million USD | 5.04% |
| 2017 Q4 | -3.77 Million USD | -246.09% |
| 2017 FY | 3.93 Million USD | -0.72% |
| 2016 FY | 3.95 Million USD | -7.53% |
| 2016 Q1 | 968.62 Thousand USD | 118.09% |
| 2016 Q4 | -3.26 Million USD | -226.0% |
| 2016 Q2 | 2.64 Million USD | 173.2% |
| 2016 Q3 | 2.59 Million USD | -2.1% |
| 2015 Q4 | -5.35 Million USD | -301.54% |
| 2015 FY | 4.28 Million USD | 30.96% |
| 2015 Q3 | 2.65 Million USD | -41.53% |
| 2015 Q2 | 4.54 Million USD | 321.45% |
| 2015 Q1 | 1.07 Million USD | 36.15% |
| 2014 FY | 3.26 Million USD | -20.72% |
| 2014 Q1 | 926.53 Thousand USD | -19.63% |
| 2014 Q2 | 852.44 Thousand USD | -8.0% |
| 2014 Q3 | 698.93 Thousand USD | -18.01% |
| 2014 Q4 | 791.99 Thousand USD | 13.31% |
| 2013 Q2 | 899.11 Thousand USD | -25.76% |
| 2013 Q4 | 1.15 Million USD | 33.82% |
| 2013 Q3 | 861.5 Thousand USD | -4.18% |
| 2013 Q1 | 1.21 Million USD | 23.92% |
| 2013 FY | 4.12 Million USD | 30.82% |
| 2012 Q4 | 977.37 Thousand USD | 55.69% |
| 2012 Q1 | 581.15 Thousand USD | -31.65% |
| 2012 FY | 3.15 Million USD | 7.17% |
| 2012 Q3 | 627.75 Thousand USD | -35.06% |
| 2012 Q2 | 966.62 Thousand USD | 66.33% |
| 2011 Q4 | 850.26 Thousand USD | 44.31% |
| 2011 Q2 | 743.52 Thousand USD | -2.04% |
| 2011 Q1 | 759.01 Thousand USD | 0.0% |
| 2011 FY | 2.94 Million USD | 0.0% |
| 2011 Q3 | 589.17 Thousand USD | -20.76% |
| 2010 Q3 | 1.05 Million USD | -12.64% |
| 2010 Q2 | 1.2 Million USD | -36.46% |
| 2010 Q1 | 1.9 Million USD | 252.29% |
| 2009 FY | 13.6 Million USD | -48.55% |
| 2009 Q4 | -1.24 Million USD | -149.83% |
| 2009 Q3 | 2.5 Million USD | -67.99% |
| 2009 Q2 | 7.83 Million USD | 40.62% |
| 2009 Q1 | 5.57 Million USD | -2.21% |
| 2008 FY | 26.43 Million USD | -44.6% |
| 2008 Q4 | 5.69 Million USD | 5.25% |
| 2008 Q1 | 5.77 Million USD | 278.16% |
| 2008 Q3 | 5.41 Million USD | -32.94% |
| 2008 Q2 | 8.07 Million USD | 39.82% |
| 2007 Q3 | 10.08 Million USD | -36.83% |
| 2007 Q1 | 14.85 Million USD | -28.95% |
| 2007 FY | 47.72 Million USD | -40.67% |
| 2007 Q4 | -3.23 Million USD | -132.13% |
| 2007 Q2 | 15.96 Million USD | 7.45% |
| 2006 Q1 | 16.46 Million USD | -41.74% |
| 2006 Q4 | 20.91 Million USD | 0.67% |
| 2006 Q3 | 20.77 Million USD | 1.37% |
| 2006 Q2 | 20.49 Million USD | 24.42% |
| 2006 FY | 80.44 Million USD | 25.79% |
| 2005 Q1 | 9.28 Million USD | -18.74% |
| 2005 Q3 | 15.27 Million USD | 44.44% |
| 2005 FY | 63.95 Million USD | 150.85% |
| 2005 Q2 | 10.57 Million USD | 13.94% |
| 2005 Q4 | 28.27 Million USD | 85.1% |
| 2004 Q4 | 11.42 Million USD | 156.27% |
| 2004 Q1 | 3.87 Million USD | 1.51% |
| 2004 Q2 | 5.51 Million USD | 42.38% |
| 2004 Q3 | 4.45 Million USD | -19.17% |
| 2004 FY | 25.49 Million USD | 94.77% |
| 2003 Q2 | 3.05 Million USD | -5.84% |
| 2003 Q1 | 3.24 Million USD | 26.14% |
| 2003 Q4 | 3.81 Million USD | 29.67% |
| 2003 FY | 13.08 Million USD | 25.12% |
| 2003 Q3 | 2.94 Million USD | -3.73% |
| 2002 Q1 | 2.25 Million USD | 7.3% |
| 2002 FY | 10.46 Million USD | 38.56% |
| 2002 Q3 | 2.72 Million USD | -7.62% |
| 2002 Q4 | 2.57 Million USD | -5.69% |
| 2002 Q2 | 2.95 Million USD | 31.19% |
| 2001 FY | 7.55 Million USD | 34.75% |
| 2001 Q4 | 2.09 Million USD | -3.25% |
| 2001 Q3 | 2.16 Million USD | 25.5% |
| 2001 Q2 | 1.72 Million USD | 11.05% |
| 2001 Q1 | 1.55 Million USD | -13.97% |
| 2000 Q1 | 1 Million USD | -42.08% |
| 2000 Q3 | 1.39 Million USD | 7.85% |
| 2000 FY | 5.6 Million USD | 14.54% |
| 2000 Q4 | 1.8 Million USD | 29.35% |
| 2000 Q2 | 1.29 Million USD | 29.5% |
| 1999 Q1 | 1.26 Million USD | -16.89% |
| 1999 Q2 | 1.09 Million USD | -13.15% |
| 1999 Q4 | 1.72 Million USD | 60.67% |
| 1999 Q3 | 1.07 Million USD | -2.07% |
| 1999 FY | 4.89 Million USD | -10.75% |
| 1998 Q2 | 1.37 Million USD | 25.78% |
| 1998 Q3 | 1.43 Million USD | 4.44% |
| 1998 Q1 | 1.09 Million USD | 0.0% |
| 1998 FY | 5.48 Million USD | 57.15% |
| 1998 Q4 | 1.52 Million USD | 5.68% |
| 1997 FY | 3.48 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -118.374% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 42.162% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 90.132% |
| Nascent Biotech, Inc. | 2.22 Million USD | -30.78% |
| Rebus Holdings, Inc. | 664 Thousand USD | -339.192% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 92.172% |
| Qrons Inc. | 643.67 Thousand USD | -353.059% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -648.586% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 94.923% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -601.897% |
| Skye Bioscience, Inc. | 13.54 Million USD | 78.474% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 96.64% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 40.702% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -1014.232% |
| SQZ Biotechnologies Company | 85.61 Million USD | 96.594% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -94.17% |
| Mesoblast Limited | 5.9 Million USD | 50.589% |
| Marizyme, Inc. | 19.23 Million USD | 84.843% |
| Genus plc | 147.7 Million USD | 98.026% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 66.783% |
| Pharming Group N.V. | 225.49 Million USD | 98.707% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -42.345% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -117.379% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 65.029% |
| ContraFect Corporation | 56.88 Million USD | 94.874% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 33.852% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -97.209% |
| IMV Inc. | 37.7 Million USD | 92.267% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -4.511% |
| MultiCell Technologies, Inc. | 567.42 USD | -513846.459% |
| ONE Bio Corp. | 6.44 Million USD | 54.744% |
| Accustem Sciences Inc. | 3.74 Million USD | 22.159% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 96.607% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -448.204% |
| Q BioMed Inc. | 3.43 Million USD | 15.143% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 88.201% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -10.988% |
| Biomind Labs Inc. | 994.18 Thousand USD | -193.33% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 97.064% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -65.725% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 56.591% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -56.419% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 11764.94% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 81.785% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -58.915% |
| GB Sciences, Inc. | 1.42 Million USD | -105.295% |
| Alpha Cognition Inc. | 9.7 Million USD | 69.953% |
| HST Global, Inc. | 140.9 Thousand USD | -1969.617% |
| CSL Limited | 3.44 Billion USD | 99.915% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -159.242% |
| Halberd Corporation | 74.84 Thousand USD | -3796.522% |
| Enzolytics Inc. | 2.17 Million USD | -33.803% |
| Agentix Corp. | 1.37 Million USD | -112.591% |
| Resverlogix Corp. | 12.71 Million USD | 77.059% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 20.119% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.81% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -179.333% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -21.261% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -84.647% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 14.354% |
| AVAX Technologies, Inc. | 7.31 Million USD | 60.108% |
| Zenith Capital Corp. | 8.94 Million USD | 67.391% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.647% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -16639.768% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -18.772% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -1600.339% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -51.816% |
| Kadimastem Ltd | 2.41 Million USD | -21.0% |
| Helix BioMedix, Inc. | 1.97 Million USD | -47.88% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 73.164% |
| BioStem Technologies, Inc. | 22.97 Million USD | 87.307% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -1506.874% |
| LadRx Corporation | 3.81 Million USD | 23.494% |
| Cell Source, Inc. | 4.32 Million USD | 32.578% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -215.777% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -215.777% |
| NovAccess Global Inc. | 2.46 Million USD | -18.221% |
| Affymax, Inc. | 39.38 Million USD | 92.596% |
| Itoco Inc. | 919.14 Thousand USD | -217.278% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 31.195% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -160.611% |
| Mobile Lads Corp. | 554.54 Thousand USD | -425.878% |
| CytoDyn Inc. | 18.05 Million USD | 83.851% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -11486.614% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -1225.092% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -105.399% |
| SYBLEU INC | 160.87 Thousand USD | -1712.722% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -60.557% |
| International Stem Cell Corporation | 5.27 Million USD | 44.674% |
| Bioxytran, Inc. | 3.82 Million USD | 23.662% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -5439.75% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -14235.324% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 91.959% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -80.237% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -296.316% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 6.261% |
| Neutra Corp. | 243.82 Thousand USD | -1096.056% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 83.295% |
| PureTech Health plc | 144.59 Million USD | 97.983% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 85.767% |
| IXICO plc | 4.7 Million USD | 38.045% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 66.85% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 97.523% |
| CSL Limited | 3.89 Billion USD | 99.925% |
| Cellectis S.A. | 97.32 Million USD | 97.003% |